betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual Read more about betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
Goldman Sachs Global Healthcare Conference Read more about Goldman Sachs Global Healthcare Conference
bluebird bio to Present at Goldman Sachs Global Healthcare Conference Read more about bluebird bio to Present at Goldman Sachs Global Healthcare Conference
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies Read more about bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4) Read more about bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD) Read more about bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma Read more about Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress Read more about bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress Read more about bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
2021 RBC Capital Markets Global Healthcare Conference Read more about 2021 RBC Capital Markets Global Healthcare Conference